{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:21:02Z","timestamp":1773289262514,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.resmer.2022.100972","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T22:05:10Z","timestamp":1667340310000},"page":"100972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effects of elexacaftor\u2013tezacaftor\u2013ivacaftor discontinuation in cystic fibrosis"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8864-2467","authenticated-orcid":false,"given":"Georgia","family":"Mitropoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zisis","family":"Balmpouzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Plojoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8500-817X","authenticated-orcid":false,"given":"Jennifer","family":"Dotta-Celio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Sauty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Koutsokera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.resmer.2022.100972_bib0001","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.resmer.2022.100972_bib0002","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.resmer.2022.100972_bib0003","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.resmer.2022.100972_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03079-2020","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"O'Shea","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.resmer.2022.100972_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.resmer.2022.100972_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21165882","article-title":"From ivacaftor to triple combination: a systematic review of efficacy and safety of CFTR modulators in people with cystic fibrosis","volume":"21","author":"Gramegna","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resmer.2022.100972_bib0007","article-title":"Ivacaftor withdrawal syndrome: a potentially life-threatening consequence from a life-saving medication","author":"Clegg","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.resmer.2022.100972_bib0008","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.resmer.2022.100972_bib0009","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jcf.2017.09.006","article-title":"Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.resmer.2022.100972_bib0010","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.resmer.2022.100972_bib0011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2019.09.013","article-title":"Ivacaftor in cystic fibrosis with residual function: lung function results from an N-of-1 study","volume":"19","author":"Nick","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.resmer.2022.100972_bib0012","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: a case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"key":"10.1016\/j.resmer.2022.100972_bib0013","article-title":"Ion transport by pulmonary epithelia","volume":"2011","author":"Hollenhorst","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"10.1016\/j.resmer.2022.100972_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041952","article-title":"Dysfunctional inflammation in cystic fibrosis airways: from mechanisms to novel therapeutic approaches","volume":"22","author":"Ghigo","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.resmer.2022.100972_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17476348.2021.2001333","article-title":"Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis","volume":"16","author":"Williamson","year":"2022","journal-title":"Expert Rev Respir Med"},{"issue":"12","key":"10.1016\/j.resmer.2022.100972_bib0016","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.resmer.2022.100972_bib0017","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chest.2017.10.005","article-title":"CORK study in cystic fibrosis: sustained improvements in ultra-low-dose Chest CT scores after CFTR modulation with ivacaftor","volume":"153","author":"Ronan","year":"2018","journal-title":"Chest."},{"key":"10.1016\/j.resmer.2022.100972_bib0018","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"Elife"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041222000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:56:07Z","timestamp":1762908967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041222000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":18,"alternative-id":["S2590041222000873"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100972","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of elexacaftor\u2013tezacaftor\u2013ivacaftor discontinuation in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2022.100972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SPLF and Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100972"}}